Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
19 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to PDS Biotechnology Corporation’s names, not what it holds today.
Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 3 in 2023
Applications published
37
1 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
PDS BIOTECHNOLOGY CORPORATION its own name
named as the applicant on its applications, in US
25 publishedPDS Biotechnology Corporation its own name
US, as the owner printed on each patent
4 publishedEDGE THERAPEUTICS, INC. a former name
US, as the owner printed on each patent
2 publishedEdge Therapeutics, Inc. a former name
named as the applicant on its applications, in US
6 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jan 21, 2025 | 12,201,685 | Methods of modulating immune responses with cationic lipid vaccine compositions | Pharmaceuticals | PDS Biotechnology Corporation |
| Feb 27, 2024 | 11,911,465 | Vaccine compositions and methods of use | Pharmaceuticals | PDS Biotechnology Corporation |
| Feb 27, 2024 | 11,911,359 | Stimulation of an immune response by cationic lipids | Pharmaceuticals | PDS Biotechnology Corporation |
| Feb 20, 2024 | 11,904,015 | Vaccine compositions and methods of use | Pharmaceuticals | PDS Biotechnology Corporation |
| Oct 31, 2023 | 11,801,257 | Stimulation of an immune response by enantiomers of cationic lipids | Pharmaceuticals | PDS Biotechnology Corporation |
| May 2, 2023 | 11,638,753 | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy | Pharmaceuticals | PDS Biotechnology Corporation |
| Mar 28, 2023 | 11,612,652 | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy | Pharmaceuticals | PDS Biotechnology Corporation |
| Aug 2, 2022 | 11,401,306 | HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof | Pharmaceuticals | PDS Biotechnology Corporation |
| Nov 10, 2020 | 10,828,364 | Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions | Pharmaceuticals | PDS Biotechnology Corporation |
| Jul 7, 2020 | 10,702,541 | Stimulation of an immune response by enantiomers of cationic lipids | Pharmaceuticals | PDS Biotechnology Corporation |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jan 16, 2025 | 2025/0018029 | METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Sep 26, 2024 | 2024/0317833 | NON-HLA RESTRICTED T CELL VACCINE FOR TCR GAMMA ALTERNATE READING FRAME PROTEIN (TARP) PROTEIN EXPRESSING CANCERS | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Sep 26, 2024 | 2024/0317828 | T CELL ACTIVATING IMMUNOTHERAPEUTIC FOR TREATMENT OF MUCIN 1 PROTEIN EXPRESSING HUMAN CANCERS | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Sep 26, 2024 | 2024/0316178 | RECOMBINANT PROTEIN VACCINES FORMULATED WITH ENANTIO-SPECIFIC CATIONIC LIPID R-DOTAP AND METHODS OF USE THEREOF | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Sep 14, 2023 | 2023/0285551 | LIPIDS AS SYNTHETIC VECTORS TO ENHANCE ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Feb 16, 2023 | 2023/0052399 | METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Oct 20, 2022 | 2022/0332768 | NOVEL HPV16 NON HLA-RESTRICTED T-CELL VACCINES, COMPOSITIONS AND METHODS OF USE THEREOF | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| May 26, 2022 | 2022/0160867 | METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Feb 3, 2022 | 2022/0031650 | STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION |
| Nov 25, 2021 | 2021/0361766 | VACCINE COMPOSITIONS AND METHODS OF USE | Pharmaceuticals | PDS BIOTECHNOLOGY CORPORATION · patent 11,911,465 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.